(PDF) P3.13-09 ALTER-0303 Study: Tumor Mutation Index (TMI)

P3.13-09 ALTER-0303 Study: Tumor Mutation Index (TMI) for Clinical Response to Anlotinib in Advanced NSCLC Patients at 3rd Line

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.08.1849

Full Text

Abstract

Available in full text

Categories

Respiratory Medicine

Date

October 1, 2018

Authors

Publisher

Elsevier BV

Related search

JCSE01.19 ALTER-0303 Study: Tumor Mutation Index (TMI) for Clinical Response to Anlotinib in Advanced NSCLC Patients at 3rd Line

Journal of Thoracic Oncology

Respiratory Medicine

English

Integrated Transcriptome Analysis Reveals KLK5 and L1CAM Predict Response to Anlotinib in NSCLC at 3rd Line

Frontiers in Oncology

Cancer Research

English

P3.13-17 a Retrospective Study: Central Nervous System Response to Osimertinib in Patients With Advanced NSCLC

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.01-108 Management of Anlotinib-Related Adverse Events: Data From ALTER 0303

Journal of Thoracic Oncology

Respiratory Medicine

English

P3.04-02 Early Plasma ctDNA Response Anticipates Clinical Response to First-Line Immunotherapy in Advanced NSCLC

Journal of Thoracic Oncology

Respiratory Medicine

English

P3.13-21 Apatinib Plus Icotinib as First-Line Therapy for EGFR Co-Mutations NSCLC in Chinese Patients: An Exploratory Study

Journal of Thoracic Oncology

Respiratory Medicine

English

P53 Mutation Analysis to Predict Tumor Response in Patients Undergoing Neoadjuvant Treatment for Locally Advanced Breast Cancer

English

Clinical Observation of Gefitinib as a First-Line Therapy in Sixty-Eight Patients With Advanced NSCLC

Oncology Letters

Cancer Research

English

P3.13-11 Advanced NSCLC Treated With Gefitinib or Erlotinib for Five Years or Longer - Retrospective Slovakian Study

Journal of Thoracic Oncology

Respiratory Medicine

English